Tsai Y.-C.TSEN-FANG TSAI2020-10-222020-10-2220191751-2433https://www.scopus.com/inward/record.uri?eid=2-s2.0-85073302745&doi=10.1080%2f17512433.2019.1665027&partnerID=40&md5=73e078dd39a2f43a0e70babe3f009668https://scholars.lib.ntu.edu.tw/handle/123456789/517538Introduction: Psoriasis is affected by many environmental factors, including infections and antibiotics. However, the relationship between antibiotics and psoriasis is inadequately studied. Some antibiotics were listed as triggering factors; others showed benefit for psoriasis control. The aim of this article is to review current evidence that may help identify appropriate antibiotics for patients with psoriasis. Areas covered: The PubMed, Embase, Clinicalkey databases, and google scholar were searched for relevant articles published up to May 2019. Literature regarding antibiotics and psoriasis were included. Six randomized controlled trials and four controlled or cohort studies were identified in 13 kinds of antibiotics. Expert opinion: Macrolides and rifampin showed decrease of psoriasis area and severity index score in plaque-type psoriasis, while penicillin revealed no statistically significant improvement in guttate psoriasis. Previously tetracyclines were considered as triggering factors, but data were found only in cases or retrospective studies. Mechanisms were thought to be related to immunomodulation rather than bacteria inhibition. Research gap in the influence of genetic susceptibility, the impact on microbiota, and the mode of actions remain to be investigated. ? 2019, ? 2019 Informa UK Limited, trading as Taylor & Francis Group.amoxicillin; Antibiotic; fusidic acid; isoniazid; macrolide; microbiota; penicillin; psoriasis; rifampin; streptococcus[SDGs]SDG3amoxicillin; antibiotic agent; azithromycin; cephalosporin derivative; clarithromycin; cotrimoxazole; doxycycline; erythromycin; fusidic acid; isoniazid; minocycline; penicillin derivative; quinolone derivative; rifampicin; roxithromycin; tetracycline; vancomycin; antiinfective agent; immunologic factor; macrolide; rifampicin; antibiotic therapy; cohort analysis; disease exacerbation; drug identification; drug use; human; psoriasis; randomized controlled trial (topic); Review; animal; pathology; psoriasis; severity of illness index; Animals; Anti-Bacterial Agents; Humans; Immunologic Factors; Macrolides; Psoriasis; Randomized Controlled Trials as Topic; Rifampin; Severity of Illness Indexreview10.1080/17512433.2019.1665027314986832-s2.0-85073302745